Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors
Location: Fairfax VA, Jacksonville FL, Tampa FL, Sarasota FL,
Sponsor: Vividion Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05954312

Phase 1, Recruiting

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

for
Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis,
Location: Providence RI, Lebanon NH, Houston TX, Aurora CO
Sponsor: 7 Hills Pharma, LLC

Sex: All

Age: 18+

Code: NCT06362369

Phase 1, Phase 2, Recruiting

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

for
Hematological Malignancy, Solid Tumor Malignancy
Location: Baltimore MD, Charlotte NC, Cincinnati OH, Seattle WA
Sponsor: Century Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05768269

Recruiting

GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors

for
Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation,
Location: Montreal
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital

Sex: All

Age: 18+

Code: NCT02333110

Recruiting

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

for
Advanced Solid Tumor Cancer
Location: Washington D.C. DC, Durham NC, Charlotte NC,
Sponsor: Immunolight, LLC

Sex: All

Age: 18+

Code: NCT04389281

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Real World Evidence on the Use of Medical Cannabis in Pediatrics

for
Cancer, Epilepsy, Neurodevelopmental Disorders
Location: Winnipeg
Sponsor: University of Manitoba

Sex: All

Age: 3 - 17

Code: NCT05863910

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

for
Locally Advanced Solid Tumors, Metastatic Solid Tumors,
Location: Scarborough ME, Boston MA, Montreal, Philadelphia PA,
Sponsor: Turning Point Therapeutics, Inc.

Sex: All

Age: 0 - 25

Code: NCT04094610

Phase 1, Phase 2, Recruiting

Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer

for
Urothelial Cancer, Cancer, Bladder Neoplasms,
Location: Burlington MA
Sponsor: Lahey Clinic

Sex: All

Age: 18+

Code: NCT00872495

Recruiting

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

for
Solid Tumor
Location: New York NY, Montreal, Chapel Hill NC, Miami FL,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT04939610

Phase 1, Phase 2, Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

for
Advanced Cancer, Advanced Solid Tumor
Location: Fairfax VA, Margate FL
Sponsor: Shanghai Allink Biotherapeutics Co., Ltd.

Sex: All

Age: 18 - 70+

Code: NCT06707610

Phase 1, Recruiting

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

for
Advanced Malignant Solid Neoplasm,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT04693468

Phase 1, Recruiting

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

for
Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma,
Location: Boston MA, New York NY, Chicago IL, Fargo ND,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0 - 17

Code: NCT02332668

Phase 1, Phase 2, Recruiting

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

for
Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
Location: Boston MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT05922501

Phase 2, Recruiting

Remote Temperature Monitoring of Patients At Risk for Developing Fever

for
Fever, Cancer, Remote Patient Monitoring
Location: Schenectady NY
Sponsor: AION Biosystems

Sex: All

Age: 18+

Code: NCT06752512

Recruiting

Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Jacksonville FL
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06640010

Recruiting

MCW Master Predict (Profile Related Evidence Determining Individualized Cancer Therapy)

for
Cancer
Location: Milwaukee WI
Sponsor: Sameem M. Abedin, MD

Sex: All

Age: 18+

Code: NCT05802069

Recruiting

A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

for
Advanced or Metastatic Solid Tumor Malignancies
Location: Bethesda MD
Sponsor: GigaGen, Inc.

Sex: All

Age: 18+

Code: NCT06258304

Phase 1, Recruiting

Telehealth Intervention for Improving Distress and Financial Toxicity in the Caregivers

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Winston-Salem NC
Sponsor: Wake Forest University Health Sciences

Sex: All

Age: 18+

Code: NCT06709404

Recruiting

Connect for Cancer Prevention Study (Connect)

for
Cancer, General Research Use
Location: Detroit MI, Atlanta GA, Marshfield WI, Minneapolis MN,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 30 - 70

Code: NCT04609072

Recruiting

High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis

for
Solid Tumor
Location: Milwaukee WI
Sponsor: Medical College of Wisconsin

Sex: All

Age: 18+

Code: NCT05301101

Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial